Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Non-Current Debt (2020 - 2025)

Bioventus (BVS) has disclosed Non-Current Debt for 6 consecutive years, with $279.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt fell 9.52% year-over-year to $279.0 million, compared with a TTM value of $279.0 million through Dec 2025, down 9.52%, and an annual FY2025 reading of $279.0 million, down 9.52% over the prior year.
  • Non-Current Debt was $279.0 million for Q4 2025 at Bioventus, down from $311.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $404.3 million in Q2 2023 and bottomed at $162.4 million in Q4 2021.
  • Average Non-Current Debt over 5 years is $327.4 million, with a median of $345.0 million recorded in 2024.
  • The sharpest move saw Non-Current Debt surged 142.0% in 2022, then fell 16.0% in 2024.
  • Year by year, Non-Current Debt stood at $339.6 million in 2021, then rose by 13.36% to $385.0 million in 2022, then fell by 4.68% to $367.0 million in 2023, then dropped by 16.0% to $308.3 million in 2024, then dropped by 9.52% to $279.0 million in 2025.
  • Business Quant data shows Non-Current Debt for BVS at $279.0 million in Q4 2025, $311.3 million in Q3 2025, and $297.9 million in Q2 2025.